Disseminated Aspergillus terreus infection arising from cutaneous inoculation treated with caspofungin

Clin Microbiol Infect. 2003 Dec;9(12):1238-41. doi: 10.1111/j.1469-0691.2003.00797.x.

Abstract

A case of disseminated Aspergillus terreus infection in a patient with prolonged neutropenia after stem cell transplant for myeloma is reported. The isolate was resistant to amphotericin B in vitro, and the patient was successfully managed with surgical debridement and the recently licensed antifungal agent caspofungin. There are many challenges associated with treating invasive aspergillosis, particularly that due to A. terreus, and the early use of caspofungin should be considered.

Publication types

  • Case Reports

MeSH terms

  • Amphotericin B / therapeutic use
  • Antifungal Agents / therapeutic use*
  • Aspergillosis / complications
  • Aspergillosis / drug therapy*
  • Aspergillus / growth & development*
  • Caspofungin
  • Dermatomycoses / complications
  • Dermatomycoses / drug therapy*
  • Dermatomycoses / microbiology
  • Drug Resistance, Fungal
  • Echinocandins
  • Humans
  • Immunocompromised Host
  • Itraconazole / therapeutic use
  • Lipopeptides
  • Male
  • Middle Aged
  • Neutropenia / microbiology
  • Peptides / therapeutic use*
  • Peptides, Cyclic*
  • Stem Cell Transplantation / adverse effects

Substances

  • Antifungal Agents
  • Echinocandins
  • Lipopeptides
  • Peptides
  • Peptides, Cyclic
  • Itraconazole
  • Amphotericin B
  • Caspofungin